PECAM-1 is a Prognostic-Related Biomarker and Correlated with Immune Infiltrates in Breast Cancer

  • Qingfang Yue Department of Medical Oncology, Shaanxi Provincial People's Hospital
  • Yuan Zhang Department of Medical Oncology, Shaanxi Provincial People's Hospital
  • Fei Cao Department of Medical Oncology, Shaanxi Provincial People's Hospital
  • Fei Wang Department of Medical Oncology, Shaanxi Provincial People's Hospital
Ariticle ID: 2771
45 Views, 18 PDF Downloads
Keywords: PECAM-1, Breast Invasive Carcinoma, Prognosis Biomarker, Methylation Immune Infiltration

Abstract

This study aims to analyze the expression and clinical significance of Platelet endothelial cell adhesion molecule 1 (PECAM-1) in breast cancer and the correlation between PECAM-1 and immune infiltrations. We performed a bioinformatic analysis of the prognostic value and immune infiltration correlation of PECAM-1 in breast cancer. The results showed that there were significant differences in PECAM-1 expression levels between breast invasive carcinoma tissues and adjacent normal tissues. The high expression of PECAM-1 was significantly related to favorable overall survival, progression-free survival and distant metastasis free survival in patients with breast cancer. There were significantly positive correlations with the levels of infiltrated B cell, CD4+T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells in breast cancer. In summary, the expression of PECAM-1 can serves as a prognostic biomarker in breast invasive carcinoma and is correlated with immune infiltrates.

References

Topalian, S.L., Drake, C.G., Pardoll, D.M.,: Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015, 27:450-461.

Gumina, R.J., Kirschbaum, N.E., Rao, P.N., vanTuinen, P., Newman, P.J.,: The human PECAM1 gene maps to 17q23. Genomics 1996, 34:229-232.

Berman ME, Xie Y, Muller WA: Roles of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) in natural killer cell transendothelial migration and beta 2 integrin activation. J Immunol 1996, 156:1515-1524.

Baldwin HS, Shen HM, Yan HC, DeLisser HM, Chung A, Mickanin C, Trask T, Kirschbaum NE, Newman PJ, Albelda SM, et al.: Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31): alternatively spliced, functionally distinct isoforms expressed during mammalian cardiovascular development. Development 1994, 120:2539-2553.

Thompson RD, Noble KE, Larbi KY, Dewar A, Duncan GS, Mak TW, Nourshargh S: Platelet-endothelial cell adhesion molecule-1 (PECAM-1)-deficient mice demonstrate a transient and cytokine-specific role for PECAM-1 in leukocyte migration through the perivascular basement membrane. Blood 2001, 97:1854-1860.

Prager E, Staffler G, Majdic O, Saemann M, Godar S, Zlabinger G, Stockinger H: Induction of hyporesponsiveness and impaired T lymphocyte activation by the CD31 receptor:ligand pathway in T.

Published
2023-04-19
How to Cite
Yue, Q., Zhang, Y., Cao, F., & Wang, F. (2023). PECAM-1 is a Prognostic-Related Biomarker and Correlated with Immune Infiltrates in Breast Cancer. Preventive Medicine Research, 12(1), 15-20. https://doi.org/10.18282/pmr.v10i2.2771
Section
Original Research Article